Compare BridgeBio Pharma Inc (BBIO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Workiva Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Workiva Inc trades at $68.78 (market cap $3.66B). The key difference: BridgeBio Pharma Inc is far larger — about 4.5× Workiva Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | WK | |
|---|---|---|
Market Cap | $16.61B | $3.66B |
Sector | Health | Technology |
52-Week High | $90.17 | $93.31 |
52-Week Low | $47.29 | $44.31 |
Enterprise Value | $18.16B | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Workiva (WK) trades at $65.14, up 4.98% with strong bullish momentum. The stock shows positive technical signals with recent earnings beats and revenue growth of 19% year-over-year in Q2 2026. Analyst consensus is overwhelmingly bullish with 16 buy ratings and an average price target of $69.00. The company's AI platform expansion and strong subscription growth support continued momentum.
Outlook remains positive with improving profitability and strategic AI investments, though high valuation multiples and RSI levels near 70 suggest potential near-term consolidation. Key risks include execution challenges and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
